Treatment of acute gout: A systematic review

Seminars in Arthritis and Rheumatism

Volumn 44, Issue 1, 2014, Pages 31-38

  Khanna, Puja P ^a   Gladue, Heather S ^b   Singh, Manjit K ^c   FitzGerald, John D ^d   Bae, Sangmee ^d   Prakash, Shraddha ^d   Kaldas, Marian ^d   Gogia, Maneesh ^d   Berrocal, Veronica ^a   Townsend, Whitney ^a   Terkeltaub, Robert ^e   Khanna, Dinesh ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b EMORY UNIVERSITY   (United States)

^c Rochester General Health System   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute gout; Systematic review

Indexed keywords

CANAKINUMAB; CELECOXIB; CHINESE DRUG; COLCHICINE; CORTICOSTEROID; CORTICOTROPIN; CYCLOOXYGENASE 2 INHIBITOR; DANGGUI NIAN TONG TANG; ETODOLAC; HERBACEOUS AGENT; ICE; INDOMETACIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PHENYLBUTAZONE; PLACEBO; PREDNISOLONE; PREDNISONE; RILONACEPT; ROFECOXIB; STEROID; TRIAMCINOLONE; UNCLASSIFIED DRUG; ANTIGOUT AGENT;

ACUTE GOUT; ANALGESIC ACTIVITY; COMPARATIVE EFFECTIVENESS; CONSERVATIVE TREATMENT; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; GOUT; HUMAN; LOW DRUG DOSE; PAIN ASSESSMENT; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VISUAL ANALOG SCALE; ACUTE DISEASE; ARTHRITIS, GOUTY; HYPERURICEMIA;

ACUTE DISEASE; ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, GOUTY; COLCHICINE; CYCLOOXYGENASE 2 INHIBITORS; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; TREATMENT OUTCOME;

EID: 84905226471     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2014.02.003     Document Type: Review

References (48)

1. Neogi T. Gout. N Engl J Med 2011, 364:443-452.
2. Zhu Y., Pandya B.J., Choi H.K. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011, 63:3136-3141.
3. So A., De Smedt T., Revaz S., Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007, 9:R28.
4. Cheng T.T., Lai H.M., Chiu C.K., Chem Y.C. A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and -meloxicam in patients with acute gouty arthritis. Clin Ther 2004, 26:399-406.
5. So A., De Meulemeester M., Pikhlak A., Yucel A.E., Richard D., Murphy V., et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010, 62:3064-3076.
6. Sarawate C.A., Patel P.A., Schumacher H.R., Yang W., Brewer K.K., Bakst A.W. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 2006, 12:61-65.
7. Terkeltaub R. Clinical practice gout. N Engl J Med 2003, 349:1647-1655.
8. Khanna D., Khanna P.P., Fitzgerald J.D., Singh M.K., Bae S., Neogi T., et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 2012, 64:1447-1461.
9. Lederman R. A double-blind comparison of etodolac and high doses of naproxen in the treatment of acute gout. Adv Ther 1990, 7:344-354.
10. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
11. Terkeltaub R.A., Furst D.E., Bennett K., Kook K.A., Crockett R.S., Davis M.W. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 2010, 62:1060-1068.
12. Ahern M.J., Reid C., Gordon T.P., McCredie M., Brooks P.M., Jones M. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med 1987, 17:301-304.
13. Shrestha M., Morgan D.L., Moreden J.M., Singh R., Nelson M., Hayes J.E. Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis. Ann Emerg Med 1995, 12:682-686.
14. Altman R.D., Honig S., Levin J.M., Lightfoot R.W. Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. J Rheumatol 1988, 15:1422-1426.
15. Eberl R., Dunky A. Meclofenamate sodium in the treatment of acute gout. Results of a double-blind study. Arzneimittelforschung 1983, 33:641-643.
16. Ruotsi A., Vainio U. Treatment of acute gouty arthritis with proquazone and indomethacin. A comparative, double-blind trial. Scand J Rheumatol Suppl 1978, 7:15-17.
17. Schumacher H.R., Boice J.A., Daikh D.I., Mukhopadhyay S., Malmstrom K., Ng J., et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. Br Med J 2002, 324:1488-1492.
18. Rubin B.R., Burton R., Navarra S., Antigua J., Londono J., Pryhuber K.G., et al. Efficacy and safety profile of treatment with etoricoxib 120mg once daily compared with indomethacin 50mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum 2004, 50:598-606.
19. Willburger R.E., Mysler E., Derbot J., Jung T., Thurston H., Kreiss A., et al. Lumiracoxib 400mg once daily is comparable to indomethacin 50mg three times daily for the treatment of acute flares of gout. Rheumatology (Oxford) 2007, 46:1126-1132.
20. Schumacher H.R., Berger M.F., Li-Yu J., Perez-Ruiz F., Burgos-Vargas R., Li C., et al. Efficacy and tolerability of celecoxib in the treatment of moderate to extreme pain associated with acute gouty arthritis: a randomized controlled trial. Arthritis Rheum 2010, S63-S64.
21. Janssens H.J., Janssen M., van de Lisdonk E.H., van Riel P.L., van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 2008, 371:1854-1860.
22. Man C.Y., Cheung I.T., Cameron P.A., Rainer T.H. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med 2007, 49:670-677.
23. Alloway J.A., Moriarty M.J., Hoogland Y.T., Nashel D.J. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol 1993, 20:111-113.
24. Axelrod D., Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum 1988, 31:803-805.
25. Terkeltaub R.A., Schumacher H.R., Carter J.D., Baraf H.S., Evans R.R., Wang J., et al. Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator. Arthritis Res Ther 2013, 15:R25.
26. Chou C.T., Kuo S.C. The anti-inflammatory and anti-hyperuricemic effects of Chinese herbal formula danggui-nian-tong-tang on acute gouty arthritis: a comparative study with indomethacin and allopurinol. Am J Chin Med 1995, 23:261-271.
27. Shi X.D., Li G.C., Qian Z.X., Jin Z.Q., Song Y. Randomized and controlled clinical study of modified prescriptions of Simiao Pill in the treatment of acute gouty arthritis. Chin J Integr Med 2008, 14:17-22.
28. Maccagno A., Di Giorgio E., Romanowicz A. Effectiveness of etodolac ('Lodine') compared with naproxen in patients with acute gout. Curr Med Res Opin 1991, 12:423-429.
29. Schumacher H.R., Berger M.F., Li-Yu J., Perez-Ruiz F., Burgos-Vargas R., Li C. Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis: a randomized controlled trial. J Rheumatol 2012, 39:1859-1866.
30. Siegel L.B., Alloway J.A., Nashel D.J. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rheumatol 1994, 21:1325-1327.
31. Schlesinger N., Alten R.E., Bardin T., Schumacher H.R., Bloch M., Gimona A., et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 2012, 71:1839-1848.
32. Daoussis D., Antonopoulos I., Yiannopoulos G., Andonopoulos A.P. ACTH as first line treatment for acute gout in 181 hospitalized patients. Joint Bone Spine 2012, 80:291-294.
33. Schlesinger N., Detry M.A., Holland B.K., Baker D.G., Beutler A.M., Rull M., et al. Local ice therapy during bouts of acute gouty arthritis. J Rheumatol 2002, 29:331-334.
34. Zhang W., Doherty M., Bardin T., Pascual E., Barskova V., Conaghan P., et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1312-1324.
35. Jordan K.M., Cameron J.S., Snaith M., Zhang W., Doherty M., Seckl J., et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007, 46:1372-1374.
36. Sivera F., Andres M., Carmona L., Kydd A.S., Moi J., Seth R., et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis 2013, 73:328-335.
37. Fernandez C., Noguera R., Gonzalez J.A., Pascual E. Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide. J Rheumatol 1999, 26:2285-2286.
38. Schlesinger N., Moore D.F., Sun J.D., Schumacher H.R. A survey of current evaluation and treatment of gout. J Rheumatol 2006, 33:2050-2052.
39. Stuart R.A., Gow P.J., Bellamy N., Campbell J., Grigor R. A survey of current prescribing practices of antiinflammatory and urate-lowering drugs in gouty arthritis. N Z Med J 1991, 104:115-117.
40. Valdes E.F. Use of tenoxicam in patients with acute gouty arthritis. Eur J Rheumatol Inflamm 1987, 9:133-136.
41. Khanna P., Khanna D. Quality of life and outcome measures. Gout & Other Crystal Arthropathies 2012, 217-224. Elsevier. 1st ed. R. Terkeltaub (Ed.).
42. Cattermole G.N., Man C.Y., Cheng C.H., Graham C.A., Rainer T.H. Oral prednisolone is more cost-effective than oral indomethacin for treating patients with acute gout-like arthritis. Eur J Emerg Med 2009, 16:261-266.
43. Wertheimer A.I., Davis M.W., Lauterio T.J. A new perspective on the pharmacoeconomics of colchicine. Curr Med Res Opin 2011, 27:931-937.
44. Singh J.A., Taylor W.J., Simon L.S., Khanna P.P., Stamp L.K., McQueen F.M., et al. Patient-reported outcomes in chronic gout: a report from OMERACT 10. J Rheumatol 2011, 38:1452-1457.
45. Weiner G.I., White S.R., Weitzner R.I., Rubinstein H.M. Double-blind study of fenoprofen versus phenylbutazone in acute gouty arthritis. Arthritis Rheum 1979, 22:425-426.
46. Reardon J.A., Stockman A., Darlington L.G., Scott J.T. Double-blind trial of feprazone and phenylbutazone in acute gout. Curr Med Res Opin 1980, 6:445-448.
47. Douglas G., Thompson M. A comparison of phenylbutazone and flufenamic acid in the treatment of acute gout. Ann Phys Med 1970, 10:275-280.
48. Butler R.C., Goddard D.H., Higgens C.S., Hollingworth P., Pease C.T., Stodell M.A., et al. Double-blind trial of flurbiprofen and phenylbutazone in acute gouty arthritis. Br J Clin Pharmacol 1985, 20:511-513.